DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,078,929
|Title:||.epsilon.-Polylysine conjugates and the use thereof|
|Abstract:||The present invention relates to .epsilon.-polylysine conjugates, in particular conjugates of .epsilon.-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney.|
|Inventor(s):||Kuebelbeck; Armin (Bensheim, DE), Larbig; Gregor (Gelnhausen, DE), Mier; Walter (Bensheim, DE), Beijer; Barbro (Nussloch, DE), Haberkorn; Uwe (Schwetzingen, DE)|
|Assignee:||Merck Patent GmbH (Darmstadt, DE)|
|Patent Claims:||1. A conjugate comprising at least one compound carrying carboxyl groups and an oligomer which consists of 10 to 1000 peptidically linked monomer units and which is
either built up from more than 50% (based on the total number of monomer units) of .epsilon.-lysine monomer units or comprises at least 10 successive monomer units which are built up from at least 70% (based on the number of such successive monomer
units) of .epsilon.-lysine monomer units, wherein the conjugate contains from 3 to 6 compounds carrying carboxyl groups per 10 monomer units, wherein, in the oligomer, said .epsilon.-lysine monomer units are bonded via the .epsilon.-amino group of their
side chain, such that the oligomer is unbranched, wherein, in the compound carrying carboxyl groups, the proportion of carboxyl groups by molecular weight is greater than 30% and wherein at least one compound carrying carboxyl groups which is conjugated
to the oligomer contains two or more free carboxyl groups.
2. The conjugate of claim 1, wherein, in addition, at least one active compound is covalently bonded to the conjugate.
3. The conjugate of claim 1, wherein the oligomer has a chain length of 10 to 50 monomer units.
4. The conjugate of claim 1, wherein the oligomer consists only of .epsilon.-lysine monomer units.
5. The conjugate of claim 1, wherein the oligomer consists of .epsilon.-polylysine.
6. The conjugate of claim 1, wherein at least one compound carrying carboxyl groups is bonded, directly or via a spacer, to the amino group of an .epsilon.-lysine monomer unit.
7. The conjugate of claim 1, wherein at least one compound carrying carboxyl groups is a complexing agent.
8. A process for the preparation of a conjugate of claim 1 which comprises at least the following process steps: a) providing an oligomer which consists of peptidically linked monomer units and which is either built up from more than 50% (based on the total number of monomer units) of .epsilon.-lysine monomer units or comprises at least 10 successive monomer units which are built up from at least 70% (based on the number of such successive monomer units) of .epsilon.-lysine monomer units, such that the oligomer is unbranched, and b) conjugating with the oligomer at least one compound carrying two or more free carboxyl groups to the oligomer from step a), wherein, optionally, at least one active compound is covalently bonded to the conjugate such that the conjugate contains from 3 to 6 compounds carrying carboxyl groups per 10 monomer units.
9. A medicament composition comprising a conjugate of claim 1.
10. A method for targeting of the kidney with a drug comprising administering the drug together with a conjugate of claim 1.
11. A macromolecule conjugate composed of at least two conjugates according to claim 1 which are covalently bonded to a macromolecule.
12. A therapeutic or image-enhancing composition, comprising a conjugate corresponding to claim 1.
13. A kit for the preparation of a medicament comprising a conjugate corresponding to claim 1.
14. A kit according to claim 13, for the preparation of a therapeutic or image-enhancing composition.
15. The conjugate of claim 2, wherein the active compound is selected from the group consisting of: immunosuppressants, cytostatics, protein kinase inhibitors, immunotherapeutic agents, antiphlogistics, antibiotics, cephalosporins, .beta.-lactamase inhibitors, carbapenems, monobactams, tetracyclines, macrolide antibiotics, glycopeptide antibiotics, enediynes, virostatics, antihypertensives, sartans, renin inhibitors, beta blockers, uricosurics, and diuretics.
16. The conjugate of claim 2, wherein the active compound is selected from the group consisting of: azathioprine, mycophenolate-mofetil, ciclosporin, tacrolimus, sirolimus, fingolimod, triptolide, bleomycin, dactinomycin, mitomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantron, amsacrine, doxofluridine, cisplatin, carboplatin, oxaliplatin, satraplatin, camptothecin, toptecan, irinotecan, etoposide, teniposide, cyclophosphamide, trofosfamide, melphalan, chlorambucil, estramustine, busulfan, chlorambucil, chlormethine, treosulfan, carmustine, lomustine, nimustine, procarbazine, streptozocine, dacarbazine, ifosfamide, temozolomide, thiotepa, vinorelbine, vincristine, vinblastine, vindesine, paclitaxel, docetaxel, methotrexate, pemetrexed, raltitrexed, fluorouracil, capecitabine, cytosinarabinoside, gemcitabine, tioguanine, pentostatin, mercaptopurine, fludarabine, caldribine, hydroxycarbamide, mitotane, azacitidine, cytarabine, nelarabine, bortezomib, anagrelide, imatinib, erlotinib, sunitinib, sorafenib, dasatinib, lapatinib or nilotinib, cetuximab, alemtuzumab, bevacizumab, naproxen, ibuprofen, indometacin, prednisolone, prednisone, hydrocortisone, budesonide, benzylpenicillin, methicillin, amoxicillin, cefuroxim, cefotaxim, cefadroxil, cefixim, clavulanic acid, sulbactam, tazobactam, imipenem, meropenem, aztreonam, tetracycline, chlortetracycline, oxytetracycline, doxycycline, minocycline, tigecycline, erythromycin A, vancomycin, calicheamicin, aciclovir, valaciclovir, ganciclovir, valganciclovir, penciclovir, famciclovir, brivudine, cidofovir, foscarnet, idoxuridine, tromantadine, benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril, zofenopril, losartan, balsartan, irbesartan, candesartan, eprosartan, olmesartan, telmisartan, aliskiren, proproanolol, pindolol, sotalol, bopindolol, atenolol, bisorpolol, celiprolol, esmolol, metoprolol, nebivolol, oxprenolol, carvedilol, labetalol, probenecid, benzbromarone, acetazolamide, furosemide, torasemide, bumetanide, piretanide, azosemide, etacrynic acid, etozoline, hydrochlorothiazide, benzthiazide, chlorothiazide, chlorthalidone, indapamide, mefruside, metolazone, clopamide, xipamide, hydroflumethiazide, methyclothiazide, polythiazide, amiloride, triameterene, spironolactone, canrenone, eplerenone and spironolactone.
17. The conjugate of claim 1, wherein the compound carrying carboxyl groups is 1,4,7,10-tetraazacyclododecane-N, -N', -N'', -N'''-tetraacetic acid or diethylenetriaminepentaacetic acid.
Summary for Patent: Start Trial
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|09009393||Jul 20, 2009|
|PCT Filed||July 09, 2010||PCT Application Number:||PCT/EP2010/004198|
|PCT Publication Date:||January 27, 2011||PCT Publication Number:||WO2011/009539|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genzyme||CAMPATH||alemtuzumab||VIAL; INTRAVENOUS||103948||001||2001-05-07||Start Trial||Merck Patent GmbH (Darmstadt, DE)||2029-07-20||RX||Orphan||search|
|Genzyme||CAMPATH||alemtuzumab||VIAL; INTRAVENOUS||103948||002||2001-05-07||Start Trial||Merck Patent GmbH (Darmstadt, DE)||2029-07-20||RX||Orphan||search|
|Genzyme||LEMTRADA||alemtuzumab||INJECTABLE;INJECTION||103948||003||2001-05-07||Start Trial||Merck Patent GmbH (Darmstadt, DE)||2029-07-20||RX||Orphan||search|
|Imclone||ERBITUX||cetuximab||VIAL; INTRAVENOUS||125084||001||2004-06-18||Start Trial||Merck Patent GmbH (Darmstadt, DE)||2029-07-20||RX||Orphan||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||001||2004-02-26||Start Trial||Merck Patent GmbH (Darmstadt, DE)||2029-07-20||RX||Orphan||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||002||2004-02-26||Start Trial||Merck Patent GmbH (Darmstadt, DE)||2029-07-20||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|South Africa||201201218||Start Trial|
|World Intellectual Property Organization (WIPO)||2011009539||Start Trial|
|United States of America||2012122788||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.